Different glucagon like peptide-1 receptor agonists have achieved therapeutic goals in Chinese patients with type 2 diabetes:Short term cost analysis
Objective This study evaluated the effect of different glucagon like peptide-1 receptor agonists(GLP-1RA)on type 2 diabetes patients in China within one year HbA1c treatment goals and relative control costs per patient for weight loss.Methods The proportion of patients who achieved single and composite endpoints related to blood glucose control,no weight gain,and hypoglycemic outcomes was obtained from SUSTAIN3,SUSTAIN7,and SUSTAIN10 studies;Calculate the number of people,annual cost,and relative control cost required to achieve clinical treatment goals based on the proportion of patients.The cost calculation is based on the annual cost of medication used by patients,expressed in 2022 Chinese medical insurance pricing RMB(CN).Results Smegglutide is more effective in achieving each endpoint and composite endpoint in patients,with fewer people(NNT)required to achieve clinical treatment goals.The cost of achieving the HbA1c＜7%target of Esenatide sustained-release agent,Dulaglutide,and Liraglutide is 4.77,1.64,2.53 times higher than that of Smeglutide,respectively;The goals of achieving HbA1c＜7%without hypoglycemia and weight gain were respectively 6.25,1.74,2.89 for smeagllutide.Conclusion Smeglutide is more cost-effective than exenatide,dulaglutide and lilalutide in the treatment of type 2 diabetes patients in China.
Type 2 diabetesSmegglutideEsenatide sustained-release agentDulaglutideLiraglutideGLP-1RACost
NETL
NSTL
万方数据
维普
